Does taking an angiotensin inhibitor increase the risk for COVID-19? – a systematic review and meta-analysisResearch Paper Published on 2021-04-302022-10-28 Journal: Aging (Albany NY) [Category] COVID-19, MERS, SARS, [키워드] 95% CI 95% confidence interval 95%CI ACE2 ACEIs adjusted adverse outcome Angiotensin converting enzyme inhibitors angiotensin receptor blocker Angiotensin receptor blockers angiotensin-converting enzyme 2 ARBs case-control study Cell Cochrane Library coronavirus disease Coronavirus disease 2019 COVID-19 COVID-19 patients database dependent on enzyme General population hypertension hypertensive incidence of COVID-19 increased risk Infection inhibitor item Meta-analysis morbidity Mortality Odds ratio pandemic performed Reporting review risk severity systematic review Topic [DOI] 10.18632/aging.202902 PMC 바로가기 [Article Type] Research Paper
Expression of the SARS-CoV-2 receptorACE2 in human heart is associated with uncontrolled diabetes, obesity, and activation of the renin angiotensin systemOriginal Investigation Published on 2021-04-272022-10-31 Journal: Cardiovascular Diabetology [Category] COVID-19, MERS, SARS, [키워드] ACE2 ACE2 expression ACE2 gene ACE2 mRNA Activation ADAM10 ADAM17 Angiotensin II angiotensin receptor blocker angiotensin-converting enzyme 2 Angiotensin-converting enzyme 2 receptor (ACE2) ARB ARBs ATII biopsies biopsy BMI body mass index clinical risk collected complex Corona virus 2 (SARS-CoV-2) correlated Degradation diabete diabetes Diabetic differentially expressed drug Ejection fraction entry of SARS-CoV-2 enzyme expressed expression facilitate Factor glycosylated heart heart tissue hearts hemoglobin higher risk human serum increase Infection infections infused inhibitor Injury investigated medication metformin mice no correlation obese patient obesity Patient plasma positively correlated protein expression RAS receptor Renin–angiotensin system blockers Result right SARS-CoV-2 serine protease serum severe disease Severe infection Support susceptibility tested the SARS-CoV-2 Therapies tissue TMPRSS2 treated Treatment virus was increased [DOI] 10.1186/s12933-021-01275-w PMC 바로가기 [Article Type] Original Investigation
Associations Between the Use of Renin–Angiotensin System Inhibitors and the Risks of Severe COVID-19 and Mortality in COVID-19 Patients With Hypertension: A Meta-Analysis of Observational StudiesCardiovascular Medicine Published on 2021-04-262022-10-31 Journal: Frontiers in Cardiovascular Medicine [Category] COVID-19, [키워드] 95% CI 95% confidence interval ACEi ACEIs acute respiratory syndrome all-cause mortality Angiotensin converting enzyme inhibitors angiotensin receptor blocker Angiotensin receptor blockers angiotensin-converting enzyme 2 appear ARB ARBs articles association Cochrane Library coronavirus Coronavirus disease 2019 COVID-19 COVID-19 patients death disease severity drug duration of hospitalization eligible entry of SARS-CoV-2 enzyme host cells hypertension inhibitor mean difference Meta-analysis Mortality no significant difference observational study participant patients with COVID-19 receptor reduction in remains uncertain risk SARS-CoV-2 Seven severe COVID-19 severe disease significant effect significantly Support System target receptor Treatment two group upregulation was performed [DOI] 10.3389/fcvm.2021.609857 PMC 바로가기 [Article Type] Cardiovascular Medicine
COVID-19 pathophysiology may be driven by an imbalance in the renin-angiotensin-aldosterone systemArticle Published on 2021-04-232022-10-04 Journal: Nature Communications [Category] MERS, SARS, 임상, 진단, 치료기술, 치료법, [키워드] ACE2 acute tubular necrosis ameliorated angiotensin receptor blocker Blood cellular entry Coagulation COVID-19 COVID-19 cohort Diffuse alveolar damage disease driven by Experimental models of disease feature increase induce inhibitor involved lung MRI Multihormonal system disorders Oxygenation pathophysiological pathophysiology patients Prognosis pulmonary artery pressure RAAS reduce retrospective SARS-CoV-2 SARS-CoV-2 receptor severe COVID-19 System Thromboembolism viral infection [DOI] 10.1038/s41467-021-22713-z PMC 바로가기 [Article Type] Article
The effects of ACE2 expression mediating pharmacotherapy in COVID-19 patientsGuideline Published on 2021-04-162022-10-30 Journal: Netherlands Heart Journal [Category] COVID-19, [키워드] ACE ACE2 ACE2 expression ACEi ACEIs acute kidney failure Acute kidney injury acute lung injury angiotensin receptor blocker ARB ARBs COVID-19 COVID-19 infected patients database demonstrated described drug Effect Evidence expression fibrosis groups Hospital admission Hospital stay hypertensive patient ICU admission increased mortality Infection Inflammation inhibitor mechanical ventilation medication methodology Mortality nine nonsteroidal anti-inflammatory drug NSAIDS outcome outcome measure pulmonary permeability question RAAS reduce renal replacement therapy Result searched severity of COVID-19 stroke suggested supplementary material susceptibility systematic analysis thromboembolic complication thromboembolic complications two groups was performed [DOI] 10.1007/s12471-021-01573-8 PMC 바로가기 [Article Type] Guideline
Influence of renin-angiotensin-aldosterone system inhibitors on plasma levels of angiotensin-converting enzyme 2안지오텐신 전환 효소 2의 혈장 수준에 대한 레닌-안지오텐신-알도스테론계 억제제의 영향Article Published on 2021-04-012022-09-11 Journal: ESC heart failure [Category] SARS, 유전자 메커니즘, [키워드] 95% confidence interval ACE ACE inhibitor ACE inhibitors ACE2 Analysis angiotensin angiotensin receptor blocker Angiotensin receptor blockers Angiotensin-converting enzyme angiotensin-converting enzyme 2 angiotensin-converting enzyme inhibitor angiotensin-converting enzyme inhibitors ARB association body mass body mass index cardiovascular disease cardiovascular risk factor cardiovascular risk factors circulating comparable Concentration concentrations concern COVID‐19 death entry receptor enzyme expression heart failure in vivo increased risk influence inhibitor lack large cohort median age Patient plasma plasma concentration Plasma levels platform positive proteomic RAAS raised Regression model SARS-CoV-2 SARS‐CoV‐2 Treatment USA was measured women [DOI] 10.1002/ehf2.13249 PMC 바로가기 [Article Type] Article
Association Between Renin-Angiotensin-Aldosterone System Inhibitors and Clinical Outcomes in Patients With COVID-19 A Systematic Review and Meta-analysisResearch Published on 2021-03-312022-10-29 Journal: JAMA Network Open [Category] COVID-19, SARS, [키워드] 95% CI ACEi ACEIs adjusted adjusted analyses Adjusted analysis Admission AEs angiotensin receptor blocker angiotensin-converting enzyme inhibitor ARB ARBs article articles assisted ventilation association assumed benefit Case series case-control studies clinical Clinical outcome clinical outcomes Clinicians Cohort studies Complication contrary coronavirus disease covariates COVID-19 cross-sectional database decrease defined diagnosed duplicates eligible evaluated exacerbate extraction finding Future higher risk hypertension Importance increased risk indicated intensive care Laboratory measure Meta-analysis Mortality multiple comorbidities objective Odds ratio outcome Patient patients with COVID-19 Point Protective radiological random-effects model randomized clinical trial receive receiving recommendation reductions in Relevance Result review risk risk of death screened searched Selection severe adverse event severe AE significant decrease significantly lower Source Study design subgroup analysis subgroup of patient synthesis System systematic review total patient total patients Treatment was used were assessed with COVID-19 [DOI] 10.1001/jamanetworkopen.2021.3594 PMC 바로가기 [Article Type] Research
Angiotensin Receptor Blockers for COVID-19: Pathophysiological and Pharmacological Considerations About Ongoing and Future Prospective Clinical TrialsPharmacology Published on 2021-03-292022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] Administered Analysis angiotensin angiotensin receptor blocker ARB blocker clinical clinical trial clinical trials COVID-19 COVID-19 pandemic diagnosis of COVID-19 doses Evidence Future initial losartan Lung inflammation moderate morbidity and mortality observational study pathway Prospective reduce renin-angiotensin system retrospective severity Support telmisartan the disease therapeutic therapeutic efficacy Trial triggered valsartan [DOI] 10.3389/fphar.2021.603736 PMC 바로가기 [Article Type] Pharmacology
Severe COVID-19 Infection Associated with Endothelial Dysfunction Induces Multiple Organ Dysfunction: A Review of Therapeutic InterventionsReview Published on 2021-03-102022-10-28 Journal: Biomedicines [Category] COVID-19, [키워드] ACE-I ACE2 Acute kidney injury angiotensin receptor blocker angiotensin-converting enzyme inhibitor ARBs ARDS association bradykinin caused chronic condition chronic disease Coagulation COVID-19 COVID-19 patients COVID-19 symptom death death in COVID-19 diabete disease Disseminated intravascular coagulation distress dysfunction Endothelial dysfunction endothelial integrity excessive inflammation excessive inflammatory response hemorrhage Immune-mediated IMPROVE induce Liver injury Mild multi-organ dysfunction Multiple multiple-organ pandemic patients review stroke Support syndrome the SARS-CoV-2 therapeutic effect therapeutic intervention thrombosis with COVID-19 [DOI] 10.3390/biomedicines9030279 PMC 바로가기 [Article Type] Review
Effects of Angiotensin-Converting Enzyme Inhibitors and Angiotensin Receptor Blockers on Angiotensin-Converting Enzyme 2 Levels: A Comprehensive Analysis Based on Animal StudiesPharmacology Published on 2021-03-082022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] ACE2 ACE2 expression ACEi ACEIs acute respiratory syndrome administration airways angiotensin angiotensin converrting enzyme angiotensin receptor blocker angiotensin-converting enzyme inhibitor animal animal study ARB ARBs blocker caused Cell cellular Chronic kidney disease Comprehensive coronavirus coronavirus disease COVID‐19 drug Effect enzyme experimental model experimental models heart failure hypertension inhibitor Lung injury Lungs majority outbreak outcome oxidative damage pandemic pathogen promoter Protective protective factor receptor report reported SARS-CoV-2 SARS‐CoV‐2 suggested Treatment viral entry virus [DOI] 10.3389/fphar.2021.619524 PMC 바로가기 [Article Type] Pharmacology